Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Australian National IBD Cohort (PANIC) study

(2021) Yanna Ko et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study

(2021) Mathurin Fumery et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis

(2020) Joseph D. Feuerstein et al.   GASTROENTEROLOGY

OP01 Higher vs. standard adalimumab maintenance regimens in patients with moderately to severely active ulcerative colitis: Results from the SERENE-UC maintenance study

(2020) J F Colombel et al.   Journal of Crohns & Colitis

IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease

(2019) Stephen B Hanauer et al.   Journal of Crohns & Colitis

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year

(2016) Peter R Gibson et al.   Clinical and Translational Gastroenterology

Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn’s disease

(2015) Sarah O’Donnell et al.   Journal of Crohns & Colitis

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Ulcerative Colitis

(2011) Silvio Danese et al.   NEW ENGLAND JOURNAL OF MEDICINE

European evidence-based Consensus on the management of ulcerative colitis: Current management

(2008) S.P.L. Travis et al.   Journal of Crohns & Colitis

European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis

(2008) E.F. Stange et al.   Journal of Crohns & Colitis